

# Mattia Boeri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1008106/mattia-boeri-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37 papers	2,186 citations	21 h-index	42 g-index
42 ext. papers	2,679 ext. citations	4.8 avg, IF	4.7 L-index

#	Paper	IF	Citations
37	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	4
36	Pathophysiology roles and translational opportunities of miRNAs in lung cancer <b>2022</b> , 245-253		
35	Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. <i>Tumori</i> , <b>2021</b> , 107, 446-451	1.7	74
34	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1298-1311	8.9	5
33	Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting.. <i>Viruses</i> , <b>2021</b> , 14,	6.2	1
32	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
31	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 617-628	4.4	3
30	Age-Related Alterations in Immune Contexture Are Associated with Aggressiveness in Rhabdomyosarcoma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6
29	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , <b>2019</b> , 132, 17-23	5.9	11
28	Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1162-1169	10.3	152
27	Exo-miRNAs as a New Tool for Liquid Biopsy in Lung Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	41
26	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 989-999	12.9	213
25	Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2746-2761	7.5	37
24	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2166-2173	12.9	47
23	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 343-357	8.9	142
22	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 869-875	3.1	9
21	Inflammatory status and lung function predict mortality in lung cancer screening participants. <i>European Journal of Cancer Prevention</i> , <b>2018</b> , 27, 289-295	2	6

20	Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 90-97	7.5	20
19	Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 922-931	8.9	10
18	Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. <i>Scientific Reports</i> , <b>2017</b> , 7, 6689	4.9	30
17	MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening. <i>Journal of Visualized Experiments</i> , <b>2017</b> ,	1.6	21
16	Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 693-699	8.9	28
15	MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. <i>Microarrays (Basel, Switzerland)</i> , <b>2016</b> , 5,		5
14	Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. <i>EBioMedicine</i> , <b>2015</b> , 2, 831-40	8.8	5
13	Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. <i>Expert Review of Molecular Diagnostics</i> , <b>2015</b> , 15, 801-13	3.8	27
12	Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. <i>Oncotarget</i> , <b>2015</b> , 6, 32868-77	3.3	57
11	DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju053	9.7	11
10	Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 768-73	2.2	290
9	Assessment of circulating microRNAs in plasma of lung cancer patients. <i>Molecules</i> , <b>2014</b> , 19, 3038-54	4.8	50
8	Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. <i>Cell Death and Disease</i> , <b>2014</b> , 5, e1564	9.8	64
7	Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2014</b> , 46, 602-6	3	1
6	Therapeutic use of microRNAs in lung cancer. <i>BioMed Research International</i> , <b>2014</b> , 2014, 756975	3	34
5	YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes. <i>Oncotarget</i> , <b>2014</b> , 5, 2608-21	3.3	52
4	Potential biomarkers for lung cancer screening. <i>Translational Lung Cancer Research</i> , <b>2014</b> , 3, 139-48	4.4	38
3	Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2012</b> , 18, 268-74	2.2	78

2	Prognostic determinants in epithelioid sarcoma. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 287-95	7.5	40
1	MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 3713-8	11.5	571